Key result
Administration of the ACE inhibitor ramipril completely inhibited the occurrence of cardiac fibrosis in rats with hypertension induced by suprarenal banding, even at a low dosage.
Why the study?
Does ramipril prevent cardiac fibrosis in rats with hypertension induced by suprarenal banding?
Does ramipril prevent cardiac fibrosis in rats with hypertension induced by suprarenal banding?
Ramipril prevents cardiac fibrosis in hypertensive rats independently of its blood pressure-lowering effects, demonstrating a direct profibrotic role of angiotensin II.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for BP-independent antifibrotic effects of ACE inhibition; leaves open translation to human hypertensive heart disease.
Hypertension induced in rats by suprarenal banding has a blood pressure elevating effect that is accompanied by the occurrence of cardiac hypertrophy and fibrosis. This phenomenon is already present at 2 weeks after banding and persists up to 1.5 years. The increase in cardiac weight is mostly due to the development of fibrosis, since myocytes are only slightly increased in size. The fibrotic tissue consists mainly of fibronectin and collagen and contains numerous cellular elements. The occurrence of fibrosis can be completely inhibited by the administration of the specific ACE inhibiting drug, ramipril, which indicated that angiotensin II may directly stimulate fibroblasts to produce fibronectin and collagen. The antifibrotic effect of ramipril was also present in a low dosage that did not lower blood pressure, confirming the hypothesis that angiotensin II has a direct effect on connective tissue cells and their ability to produce extracellular matrix proteins. The direct effect of the renin-angiotensin system on the activity of interstitial cells was further proven by molecular biology techniques showing an upregulation of transcription for collagen I and III which is prevented by ACE inhibition.
No takes yet. Share an insight, caveat, or question.
Nagasawa et al. (1995) studied Hypertension-induced cardiac hypertrophy and fibrosis. Ramipril was evaluated on Cardiac fibrosis (extracellular matrix deposition). Administration of the ACE inhibitor ramipril completely inhibited the occurrence of cardiac fibrosis in rats with hypertension induced by suprarenal banding, even at a low dosage.
Synapse has enriched 10 related papers. Consider them for comparative context: